PPD (PPD) Aktsia Kursus

PPD Kursus

NASDAQ·SULETUD
47,28
​
Turg suletud

Käive kasvas 15,0 % aastas viimase 4 aasta jooksul 4,68 B USD-ni. Kasum aktsia kohta langes 5,9 % aastas viimase 4 aasta jooksul. PPD netomarginaal on nüüd 3,3 %, langenud 6,8 %-lt mõni aasta tagasi.

PPD aktsiahinnad

Hangi need andmed Eulerpool API kaudu

100 000 päringut/kuus tasuta · krediitkaarti pole

PPD ärimudel ja aktsia analüüs

PPD Inc on globaalne meditsiiniuuringute ja -teenuste ettevõte, mis asutati 1985. aastal ja mille peakontort asub Wilmingtonis Põhja-Carolina osariigis USA-s. Ettevõte on tuntud oma võime poolest läbi viia kliinilisi uuringuid ja arendada uurimisprogramme biopharma- ja meditsiinisektori jaoks. PPD on juhtiv pakkuja terviklikele, integreeritud teenustele I–IV faasi kliinilistes uuringutes, alates mittesekkuvatest uuringutest kuni lepinguliste uuringuteni farmaatsia- ja biotehnoloogia klientidele. PPD ärimudel põhineb kolmel põhipostil, et pakkuda klientidele laia valikut teenuseid: esimene post hõlmab terviklikke kliinilisi uuringuid, mida nõuavad ravimite registreerimiseks regulatiivsete asutustega; teine post keskendub uurimisandmete ja analüüsimeetodite pakkumisele, et lihtsustada otsustamist ja riskihindamist tervishoiusektoris; ning kolmas post hõlmab ulatuslikke laborianalüüse ja diagnostilisi teste, et parandada patsientide tervist ja toetada uurimistööd. PPD-l on mitu osakonda, mis on suunatud konkreetsetele turgudele ja klientidele. Kliiniliste uuringute osakond pakub teenuseid ravimite arendamiseks kuni regulatiivsete asutuste heakskiiduni, sealhulgas kliiniliste uuringute korraldamist ja jälgimist ning tulemuste statistilist analüüsi. Andmehalduse osakond pakub andmekogumise ja -halduse lahendusi kliinilisteks uuringuteks, tagades kõrge andmekvaliteedi ja regulatsioonide vastavuse. Meditsiinilise jälgimise osakond pakub meditsiinilist konsultatsiooni ja jälgimist kliiniliste uuringute ajal. PPD-l on ka osakond Reaalse Maailma Tõendite (Real World Evidence) uuringuteks, mis kogub andmeid tavapärasest kliinilisest praktikast, et hinnata ravimite ohutust ja efektiivsust. PPD on minevikus teinud olulisi omandamisi, et tugevdada oma kohalolekut tööstuses. 2011. aastal ostsid privaatkapitalifirmad Carlyle Group ja Hellman & Friedman PPD, muutes selle eraettevõtteks. 2020. aastal läks PPD börsile. 2018. aastal omandas PPD Evidera, ettevõtte, mis on spetsialiseerunud kliinilisele epidemioloogiale ja tulemusuurimisele. 2019. aastal omandas PPD Q-Squared Solutions, laiendades oma ulatuslikke laborianalüüsi ja diagnostiliste testide võimalusi. PPD pakkumised hõlmavad laia valikut tooteid ja teenuseid, sealhulgas unikaalseid planeerimis- ja rakenduslahendusi, mis võimaldavad kliinilisi uuringuid tõhusalt läbi viia. Need lahendused hõlmavad ka elektroonilisi andmekogumise ja -halduse süsteeme ning statistilise analüüsi tööriistu. PPD pakub ka erialaseid teenuseid, nagu koolitusprogrammid kliinilistele uurijatele ja personalile. PPD eesmärk on võimaldada ohutumat, kiiremat ja kuluefektiivsemat ravimite arendamist läbi kliiniliste uuringute. Tulevikus jätkab PPD oma ärimudeli ja teenuste laiendamist, et rahuldada oma klientide vajadusi muutumas tööstuses ja toetada innovaatilisi uurimisprogramme.

Korduma kippuvad küsimused PPD aktsia kohta

PPD Inc is a leading global contract research organization (CRO) providing comprehensive, integrated drug development and laboratory services. Their business model revolves around offering end-to-end solutions to pharmaceutical and biotech companies, guiding them through the entire drug development process. PPD Inc offers a wide range of services including clinical research, data management, biostatistics, and regulatory affairs. With a focus on quality, efficiency, and innovation, PPD Inc helps clients accelerate the development of life-changing therapies. Through their extensive expertise, efficient processes, and strategic partnerships, PPD Inc plays a crucial role in advancing healthcare outcomes and bringing new treatments to patients worldwide.

PPD Inc is primarily active in the pharmaceutical and biotechnology industries.

The main competitors of PPD Inc in the market include QuintilesIMS, LabCorp, Icon, and Covance.

PPD Inc is a leading global contract research organization (CRO) specializing in drug development, laboratory services, and clinical trial management. Founded in 1985, PPD has a rich history and a strong background in providing innovative solutions to the pharmaceutical, biotechnology, and medical device industries. The company offers a comprehensive range of services, including early development, clinical research, laboratory services, and post-approval studies. PPD Inc has established itself as a trusted partner for the life sciences industry, delivering high-quality results, efficiency, and expertise in advancing healthcare solutions. With a global presence and a team of experienced professionals, PPD continues to be at the forefront of advancing clinical research and improving patient outcomes.

PPD Inc has achieved significant milestones throughout its history. Some noteworthy achievements include successfully conducting over 230,000 clinical trials, establishing a global presence in more than 46 countries, and consistently delivering innovative solutions to the life sciences industry. The company has also been recognized for its exceptional expertise in clinical research, data management, and regulatory affairs. PPD Inc's commitment to quality and customer satisfaction has enabled it to be a reliable partner for pharmaceutical, biotechnology, and medical device companies worldwide. With its strong track record and industry leadership, PPD Inc continues to make significant strides in advancing healthcare and improving patient outcomes.

PPD Inc primarily operates in over 50 countries and regions worldwide. With a strong global presence, the company offers its comprehensive range of clinical research and laboratory services to clients across various industries. PPD Inc's key markets include the United States, Europe, Asia Pacific, and Latin America. The company's extensive network and expertise allow it to effectively serve clients on a global scale, helping them navigate the complexities of drug development and deliver innovative solutions. PPD Inc's commitment to expanding its presence in emerging markets reinforces its position as a leading provider of life sciences services worldwide.

PPD Inc represents a strong set of values and a clear corporate philosophy. The company focuses on delivering exceptional customer service, fostering a culture of innovation, and maintaining the highest standards of integrity. PPD Inc aims to provide reliable and efficient solutions in the fields of healthcare and clinical research. With its commitment to excellence, PPD Inc strives to deliver value to its clients and contribute to better patient outcomes. The company's dedication to these principles has established it as a trusted leader in the industry, making PPD Inc a go-to choice for businesses and individuals seeking reliable healthcare and clinical research services.

Praeguse kursiga kaubeldakse PPD aktsiaga 42,10 EUR (47,28 USD) juures.

PPD aktsia (PPD) on noteeritud 1 börsil, sh: NASDAQ (PPD).

PPD Inc is an international pharmaceutical company headquartered in the USA with branches in Europe, Asia, Africa, and Australia. The company operates in the areas of clinical research, pharmacovigilance, laboratory services, and consulting, offering comprehensive solutions to its clients for the development, approval, and monitoring of drugs and medical devices. One of PPD's main divisions is clinical research. The company works closely with pharmaceutical and biotechnology companies, as well as academic research institutions, to conduct clinical trials. PPD provides all the necessary services for conducting a clinical trial, from study design to subject recruitment, data analysis, and reporting. PPD has extensive experience in all phases of clinical research, from Phase I to Phase IV, and has successfully brought numerous drugs to market in the past. Another important division of PPD is pharmacovigilance. Here, the company collects and analyzes data on adverse drug reactions and provides recommendations for risk minimization. PPD works closely with regulatory authorities worldwide to ensure that all data on adverse drug reactions are accurately recorded and analyzed. In addition, PPD offers laboratory services. The company's portfolio includes a wide range of laboratory tests, including bioanalytical tests and safety tests. PPD has extensive expertise in analyzing biological samples, including blood, urine, saliva, and stool samples. The company specializes in identifying molecular markers that are important for disease diagnosis or monitoring therapy success. PPD also offers comprehensive consulting services. Here, the company supports its clients in the development of new therapies and drugs and provides recommendations for optimizing study design and methods. PPD has extensive experience in working with the FDA and other regulatory authorities worldwide, developing strategies for risk minimization and compliance with regulatory requirements. PPD offers a wide range of products and services specifically tailored to the needs of pharmaceutical and biotechnology companies. The company is committed to offering innovative solutions to its clients to accelerate the development of new drugs and therapies. To this end, PPD has made significant investments in its research and development activities in recent years and works closely with customers and partners to develop new and innovative treatment options. Overall, PPD's business model is oriented towards the needs of the pharmaceutical and biotechnology industry. The company offers comprehensive solutions to its clients for the development, approval, and monitoring of drugs and medical devices. PPD is a key partner for innovation in drug development and has successfully brought numerous therapies and drugs to market in the past.

Käivet ei saa praegu PPD kohta arvutada.

Kasumit ei saa praegu PPD kohta arvutada.

P/E-suhtarvu ei saa praegu PPD kohta arvutada.

P/S-suhtarvu ei saa praegu PPD kohta arvutada.

Eulpooli kvaliteedinäitaja PPD jaoks on 4/10.

PPD ISIN on US69355F1021. ISIN (rahvusvaheline väärtpaberi identifitseerimise number) on väärtpaberite globaalne unikaalne tuvastaja.

PPD WKN on A2PX5V. WKN (Wertpapierkennnummer) on kuuekohaline saksa väärtpaberi identifitseerimise number.

PPD ticker on PPD. Ticker-sümbol kasutatakse PPD aktsiate kauplemiseks börsil.

Õiglane väärtusTerminal
50,12 USD
Üle-/alahinnangTerminal
Õiglaselt hinnatakse
Tööstus
Eluteaduste tööriistad ja teenused
Aktsiate arv
Töötajad
Tulu töötaja kohta
203 542,35 USD
Tulukasvu keskmine 5 aastat
EBIT kasvu keskmine 5 aastat
Puhaskasumi kasvu keskmine 5 aastat
Veebisait ppd.com
Valuuta
USD
Börsi noteerimise algus
6. veebr 2020
ISIN
US69355F1021
CUSIP
69355F102
SEDOL
BL9BT47
Turukapitalisatsioon
16,55 B USDLarge Cap
52-nädala vahemik
PEG
—
P/E suhe
P/E e 2021
29,19
P/E e 2022
25,56
P/E e 2023
22,49
P/E e 2024
19,94
P/E e 2025
17,50
P/S
P/S e
2,73
EV/EBIT
—
P/B suhe
—
ROE (omakapitali tootlus)
ROA (varatootlus)
ROCE (kasutatud kapitali tootlus)
ROIC (investeeritud kapitali tootlus)
4,37 %
Viimati värskendatud 6. nov 2026, 03:36

Kõik teised näitajad ja analüüsid PPD kohta sügavamalt

Meie PPD-aktsia analüüs sisaldab olulisi finantsnäitajaid, nagu käive, kasum, P/E suhe, P/S suhe, EBIT, samuti teavet dividendi kohta. Lisaks käsitleme aspekte nagu aktsiad, turukapitalisatsioon, võlad, omakapital ja kohustused ettevõttes PPD. Kui otsite nende teemade kohta põhjalikumat teavet, pakume teile meie alamlehtedel üksikasjalikke analüüse: